This article is more than 5 years old. Information may no longer be current.

RepRegen receives CE mark approval for strontium-based bioactive glass platform

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RepRegen, which calls itself the “smart biomaterials” company and previously known as BioCeramic Therapeutics, announced in a press release that it has received CE marking approval for StronBone bioactive glass with strontium, the first product that will be commercialized from the company’s repair-and-regeneration platform of “smart” biomaterials for hard tissue, such as bone.

“This European regulatory approval enables us to fast-forward the discussions we are having with several potential strategic partners about our hard tissue platform, in general, and our StronBone product, in particular,” Ian Brown, RepRegen's CEO, stated in the press release.

“We have previously said that the business opportunities ahead of RepRegen are significant and that some of these opportunities are near-term," added Chairman Dr. Stephen Rietiker. "The company's ‘smart’ biomaterials related to its hard tissue platform represent great new medical device products for the orthopedic biomaterials market sector that will be well-received.”